Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
US Army
Argus Health
Accenture
Federal Trade Commission
Chubb
Baxter
Covington

Generated: May 27, 2018

DrugPatentWatch Database Preview

Claims for Patent: 5,804,570

« Back to Dashboard

Summary for Patent: 5,804,570
Title: Method of lessening the risk of non-vertebral bone fractures
Abstract:Alendronate, a bisphosphonate, when administered daily over a substantial period of time, can reduce the rate of non-vertebral fractures, in post-menopausal women.
Inventor(s): Santora, II; Arthur C. (Watchung, NJ), Karpf; David B. (North Brunswick, NJ), Polvino; William J. (Bridgewater, NJ), Shapiro; Deborah Ruth (Edison, NJ), Thompson; Desmond E. (Martinsville, NJ), Yates; Ashley John (Westfield, NJ)
Assignee: Merck & Co., Inc. (Rahway, NJ)
Application Number:08/867,987
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 5,804,570
Patent Claims: 1. A method of reducing the risk of non-vertebral fractures in an osteoporotic female comprising administering an effective amount of alendronate or a pharmaceutically acceptable salt thereof.

2. The method according to claim 1 wherein the alendronate is administered orally.

3. The method according to claim 2 wherein the dose is from 2.5 mg to 20 mg daily.

4. The method according to claim 3 wherein the dose is 10 mg daily.

5. The method according to claim 2 wherein the alendronate is administered substantially daily for a period of more than two years.

6. The method according to claim 2 wherein the alendronate is administered substantially daily for a period of at least about three years.

7. The method according to claim 1 wherein the female is elderly.

8. A method of reducing the risk of non-vertebral bone fractures in an osteoporotic postmenopausal female comprising administering to the female from 2.5-20 mg of alendronate or a pharmaceutically acceptable salt thereof substantially daily for a substantial period of time.

9. A method according to claim 8 wherein the female is elderly.

10. The method according to claim 1 wherein the alendronate is administered for a substantial period of time.

11. The method according to claim 3 wherein the dose is 2.5 mg daily.

12. The method according to claim 3 wherein the dose is 5 mg daily.

13. The method according to claim 8 wherein the dose is 2.5 mg daily.

14. The method according to claim 8 wherein the dose is 5 mg daily.

15. The method according to claim 8 wherein the dose is 10 mg daily.

16. The method according to claim 8 wherein the dose is 20 mg daily.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
US Department of Justice
McKinsey
Healthtrust
Fish and Richardson
QuintilesIMS
Federal Trade Commission
UBS
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.